Cargando…

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease

Chronic granulomatous disease is an inborn error of immunity due to disrupted function of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. This results in impaired respiratory burst of phagocytes and insufficient killing of bacteria and fungi. Patients with chronic granulomat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheiermann, Julia, Künkele, Annette, von Stackelberg, Arend, Eggert, Angelika, Lang, Peter, Zirngibl, Felix, Martin, Luise, Schulte, Johannes Hubertus, von Bernuth, Horst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978143/ https://www.ncbi.nlm.nih.gov/pubmed/36875143 http://dx.doi.org/10.3389/fimmu.2023.1042650

Ejemplares similares

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022)

T‐cell depleted HLA‐haploidentical HSCT in a child with neuromyelitis optica
por: Ceglie, Giulia, et al.
Publicado: (2019)

Allogeneic HSCT for Symptomatic Female X-linked Chronic Granulomatous Disease Carriers
por: Tsilifis, Christo, et al.
Publicado: (2023)

Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia
por: Andreani, Marco, et al.
Publicado: (2017)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies
por: Zhang, Fei, et al.
Publicado: (2013)

Deciphering the biology of KIR2DL3(+) T lymphocytes that are associated to relapse in haploidentical HSCT
por: David, Gaëlle, et al.
Publicado: (2021)

Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
por: Liu, Zenghui, et al.
Publicado: (2020)

Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report
por: Baldo, Francesco, et al.
Publicado: (2021)

Targeting subtype in ALL
por: von Stackelberg, Arend
Publicado: (2019)

Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.
por: Kim, K. Y.
Publicado: (1986)

Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT
por: Zaghi, Elisa, et al.
Publicado: (2021)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

PB2417: PRESENCE´S IMPACT OF NON-SPECIFIC ANTI-HLA ANTIBODIES ON THE DEVELOPMENT OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING PERIPHERAL BLOOD HAPLOIDENTICAL HSCT, EXPERIENCE AT A CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
por: Roy, Denis Claude, et al.
Publicado: (2020)

Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide
por: Toyosaki, Masako, et al.
Publicado: (2018)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia
por: Tsushima, Takafumi, et al.
Publicado: (2022)

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
por: McCurdy, Shannon R., et al.
Publicado: (2015)

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
por: Künkele, Annette, et al.
Publicado: (2013)

Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial
por: Wang, Yu, et al.
Publicado: (2022)

Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease
por: Bhat, Deepali K., et al.
Publicado: (2021)

T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients
por: Sodani, Pietro, et al.
Publicado: (2011)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?
por: Ab Rahman, Syaza, et al.
Publicado: (2022)

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
por: Jin, Xin, et al.
Publicado: (2019)

Haploidentical CD3(+) TCR αβ/CD19(+)–depleted HSCT for MHC class II deficiency and persistent SARS-CoV-2 pneumonitis
por: Ramanathan, Subramaniam, et al.
Publicado: (2022)

PB2462: IMPACT OF ENGRAFTMENT SYNDROME ON THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC/HAPLOIDENTICAL PERIPHERAL BLOOD HSCT IN A SINGLE CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

CD4(+)FOXP3(+) Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2019)

IntReALL HR and the benefits of adaptive design
por: Holmes, Jane, et al.
Publicado: (2015)

Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
por: Santos, Paulo Sérgio da Silva, et al.
Publicado: (2023)

Dental consensus on HSCT – Part II: dental Care during HSCT
por: Gobbi, Marcella Ferreira, et al.
Publicado: (2023)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s01ce2u072ps2ocs6uaohp920c